Inclusion Criteria

- INCLUSION CRITERIA:

1. The patient must have histologically or cytologically proven peritoneal
carcinomatosis from low-grade mucinous adenocarcinoma of the gastrointestinal
tract. Patients with no tissue for examination may undergo percutaneous needle
aspiration under computed tomography (CT) or ultrasound guidance as clinically
indicated or a laparotomy with biopsy if a tumor grade cannot be determined on
other available material.

2. Radiologic workup must demonstrate that there is no imageable disease outside of
the peritoneal cavity.

3. Radiologic workup or prior abdominal exploration must show abnormalities
consistent with disease which can be debulked to a residual size of less than 1
cm in diameter per tumor deposit in the judgement of the investigators.

4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance
status of less than or equal to 2 on study entry and on the day prior to planned
treatment.

5. Patients must have a minimum expected duration of survival of greater than 16
weeks.

6. Patients must have recovered from any severe toxicity from all prior
chemotherapy, immunotherapy or radiotherapy except as outlined in appendix 1 of
the protocol and be at least 30 days past the date of their last treatment.

7. Patients must have a serum aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) within 5 times the upper limit of normal and a total
serum bilirubin of less than 3 times the upper limit of normal, both of which
define the upper limit of grade 2 treatment related toxicities..

8. Patients must have a absolute neutrophil count (ANC) greater than
1,500/microliter.

9. Patients must be age greater than or equal to 18 years.

EXCLUSION CRITERIA:

1. Patients will be excluded if they have concomitant medical problems that would place
them at unacceptable risk for a major surgical procedure.

1. Patients at increased risk for coronary artery disease or cardiac dysfunction
(e.g. age greater than 65, and a history of hypertension, first degree relative
with atherosclerotic coronary artery evaluation and will not be eligible if they
demonstrate significant irreversible ischemia on a stress thallium study or an
ejection fraction of less than 40%.

2. Patients who have shortness of breath with minimal exertion or who are at risk
for pulmonary disease (e.g., chronic smokers) will undergo pulmonary function
testing and will not be eligible if their forced expiratory volume 1 (FEV1) is
less than 1.2 liters or their maximum voluntary ventilation is less than 50% of
expected.

2. Patients who have a neurological toxicity of Grade 3 or greater will be excluded
because of the potential neurotoxicity associated with platinum and paclitaxel
therapy.

3. Patients will be ineligible if they have a serum creatinine of greater than 1.5 mg/dL
unless the measured creatinine clearance is greater than 60mL/min/1.73m^2.

4. Patients will be ineligible if platelets are less than 75, 000/mm^3.

5. Patients who have failed previous intraperitoneal chemotherapy will be ineligible.

6. Pregnant women or women who are breast-feeding will be ineligible.

7. Patients less than 30 kg will be ineligible.

8. Patients who have undergone two or more operative procedures to debulk disease, have
received 2 or more regimens of systemic chemotherapy, or any previous continuous
hyperthermic peritoneal perfusion (CHPP) therapy will be excluded from study.